Young Therapeutics was founded in 2015 by Dr. Lindon Young, professor of pharmacology at Philadelphia College of Osteopathic Medicine.
Dr. Young has dedicated his career to understanding the phenomenon of ischemia/reperfusion
injury (I/R I) that occurs when an organ is subjected to a period of inadequate blood
supply followed by the reestablishment of blood flow. Paradoxically, restoration of
blood flow causes additional damage through the production of oxygen free radicals.
Dr. Young discovered small molecules that inhibit various forms of the enzyme protein kinase C that leads to the generation of oxygen free radicals. Studies supported by the NIH SBIR program demonstrated that these inhibitors prevent I/R damage in isolated hearts and preserve heart function in animals.
I/R I also impairs the function of transplanted kidneys and results in premature organ failure. Based on their data, the FDA granted Orphan Drug Status for use of these molecules in kidney transplantation.
Young Therapeutics' patented technology has evolved to increase specificity and effectiveness for the prevention of I/R I. Ongoing studies include long-term assessments of the heart and kidneys to determine if the inhibitors reduce the incidence of organ failure. Toxicology and pharmacokinetic and pharmacodynamic assessments will pave the way for human clinical studies.
© 2025 Philadelphia College of Osteopathic Medicine